πŸ‡ΊπŸ‡Έ FDA
Patent

US 12371434

MLL1 inhibitors and anti-cancer agents

granted A61KA61K31/437A61K31/52

Quick answer

US patent 12371434 (MLL1 inhibitors and anti-cancer agents) held by CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD.
Grant date
Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/437, A61K31/52, A61K31/53, A61K45/06